Search Result

Results for "

Y-{d-Trp}-GFM-NH2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Bacterial (2) Biochemical Assay Reagents (3) Bombesin Receptor (2) Deubiquitinase (1) Drug Derivative (1) Endothelin Receptor (1) Fungal (1) GHR (1) GHSR (2) GnRH Receptor (6) Interleukin Related (1) JNK (1) Kisspeptin Receptor (3) Melanocortin Receptor (4) Neurokinin Receptor (18) Neuropeptide Y Receptor (2) Neurotensin Receptor (1) Opioid Receptor (4) Oxytocin Receptor (1) Proteasome (1) PTHR (1) Radionuclide-Drug Conjugates (RDCs) (9) Somatostatin Receptor (20) Thyroid Hormone Receptor (1) Urotensin Receptor (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (8) Endocrinology (14) Infection (3) Inflammation/Immunology (8) Metabolic Disease (8) Neurological Disease (23)

By Targets:

Apoptosis (3)

Bacterial (2)

Biochemical Assay Reagents (3)

Bombesin Receptor (2)

Deubiquitinase (1)

Drug Derivative (1)

Endothelin Receptor (1)

Fungal (1)

GHR (1)

GHSR (2)

GnRH Receptor (6)

Interleukin Related (1)

JNK (1)

Kisspeptin Receptor (3)

Melanocortin Receptor (4)

Neurokinin Receptor (18)

Neuropeptide Y Receptor (2)

Neurotensin Receptor (1)

Opioid Receptor (4)

Oxytocin Receptor (1)

Proteasome (1)

PTHR (1)

Radionuclide-Drug Conjugates (RDCs) (9)

Somatostatin Receptor (20)

Thyroid Hormone Receptor (1)

Urotensin Receptor (1)

Vasopressin Receptor (1)

By Research Areas:

Cancer (30)

Cardiovascular Disease (8)

Endocrinology (14)

Infection (3)

Inflammation/Immunology (8)

Metabolic Disease (8)

Neurological Disease (23)

Inhibitors & Agonists

Peptides

Targets Recommended: TRP Channel

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1276A

Men 10376 TFA 1 Publications Verification Neurokinin-2 receptor antagonist TFA	Neurokinin Receptor	Endocrinology
Men 10376 TFA is a selective tachykinin NK-2 receptor antagonist, with a K_i of 4.4 μM for rat small intestine NK-2 receptor .

HY-P1194A

Spantide I TFA	Neurokinin Receptor	Inflammation/Immunology
Spantide I TFA, a substance P analog, is a selective NK₁ receptor antagonist, with K_i values of 230 nM and 8150 nM for NK₁ and NK₂ receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation ^[2] .

HY-P1194

Spantide I	Neurokinin Receptor	Inflammation/Immunology
Spantide I, a substance P analog, is a selective NK₁ receptor antagonist, with K_i values of 230 nM and 8150 nM for NK₁ and NK₂ receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation ^[2] .

HY-P1194B

[D-Pro2] Spantide I TFA	Neurokinin Receptor	Neurological Disease
[D-Pro2] Spantide I TFA is a Spantide analog. Spantide I is a selective NK1 receptor antagonist .

HY-P3540

*Y-{d-Trp}-GFM-NH2*	Biochemical Assay Reagents	Others
Y-{d-Trp}-GFM-NH2 is an active peptide. Y-{d-Trp}-GFM-NH2 can be used for the research of various biochemical studies .

HY-P2439

MEN 10208	Neurokinin Receptor	Others
MEN 10208 is a neurokinin A antagonist prepared by solid phase synthesis. The Fmoc strategy has more advantages than the Boc strategy in its preparation, and can obtain products with higher yield and purity.

HY-P10673

KwFwLL-NH2	GHSR	Metabolic Disease
KwFwLL-NH2, a hexapeptide, is a ghrelin receptor ligand. KwFwLL-NH2 can act as a specific inverse agonist at the ghrelin receptor but with moderate potency (EC₅₀=45.6 nM) .

HY-P1276

Men 10376 Neurokinin-2 receptor antagonist	Neurokinin Receptor	Endocrinology
Men 10376 is a selective tachykinin NK-2 receptor antagonist, with a K_i of 4.4 μM for rat small intestine NK-2 receptor.

HY-P3671

[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH	GnRH Receptor	Endocrinology
[D-Glp1,D-Phe2,D-Trp3,6]-LH-RH is a Luteinizing-hormone-releasing hormone (LHRH) analogue. [D-Glp1,D-Phe2,D-Trp3,6]-LH-RH acts as a GnRH receptor antagonist .

HY-P3880

(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P	Neurokinin Receptor	Neurological Disease
(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P is a neuropeptide Substance P (HY-P0201) antagonist .

HY-P3225

(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P acetate	Bombesin Receptor Neurokinin Receptor	Neurological Disease Inflammation/Immunology
(D-Arg1,D-Pro2,D-Trp7,9,L-Leu11)-Substance P (acetate) is an antagonist for Substance P (HY-P0201) and Bombesin (HY-P0195) that has effects on ocular inflammatory responses to antidromic trigeminal nerve stimulation .

HY-P3850

(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B	Neurokinin Receptor	Neurological Disease
(D-Pro2,D-Trp6,8,Nle10)-Neurokinin B is a competitive antagonist of Neurokinin B (Neurokinin Receptor) with a pA2 of 5.5. (D-Pro2,D-Trp6,8,Nle10)-Neurokinin B shows no influence on Substance P or Neurokinin A .

HY-P1217

[D-Trp8]-γ-MSH	Melanocortin Receptor	Inflammation/Immunology
[D-Trp8]-γ-MSH is a potent and selective agonist of melanocortin 3 (MC3) receptor, with IC₅₀s of 6.7 nM, 600 nM and 340 nM for hMC3, hMC4 and hMC5, respectively in CHO cells. [D-Trp8]-γ-MSH could provide protection against multiple inflammatory disorders such as rheumatoid arthritis and colitis ^[2].

HY-103544

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P	JNK Interleukin Related Bombesin Receptor	Inflammation/Immunology Cancer
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P, a Substance P derivative, is a biased agonist toward neuropeptide and chemokine receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P activates G12. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P binds to IL-8 and GRP receptors. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P inhibits ERK-2 activation, activates JNK activity. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P stimulates an increase in neutrophil migration and Ca ²⁺ mobilization. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-Substance P is also a bombesin antagonist, and inhibits the growth of small cell lung cancer ^[2]

HY-P5591

PAF26	Fungal	Infection
PAF26 is an antimicrobial peptide against phytopathogenic fungi Penicillium digitatum, Penicillium italicum and Botrytis cinerea .

HY-P3057

[D-Trp11]-Neurotensin	Neurotensin Receptor	Cardiovascular Disease Neurological Disease
[D-Trp11]-Neurotensin, an analogue of Neurotensin (NT), is a selective antagonist of NT in perfused rat hearts but behaves as a full agonist in guinea pig atria and rat stomach strips. [D-Trp11]-Neurotensin can inhibit NT-induced hypotension ^[2].

HY-P4572

(D-Trp6)-LHRH free acid	GnRH Receptor	Cancer
(D-Trp6)-LHRH free acid is a luteinizing hormone-releasing hormone (LHRH) agonist .

HY-P1322

[D-Trp34]-Neuropeptide Y	Neuropeptide Y Receptor	Neurological Disease
[D-Trp34]-Neuropeptide Y is a potent and selective neuropeptide Y (NPY) Y₅ receptor agonist. [D-Trp34]-Neuropeptide Y is a significantly less potent agonist at the NPY Y₁, Y₂, Y₄, and y₆ receptors. [D-Trp34]-Neuropeptide Y markedly increases food intake in rats ^[2].

HY-P4385

(Asn10,Leu11,D-Trp12)-pTH-Related Protein (7-34) amide (human, mouse, rat)	PTHR	Metabolic Disease
(Asn10,Leu11,D-Trp12)-pTH-Related Protein (7-34) amide (human, mouse, rat) is a potent PTH-1R antagonist ^[2].

HY-P1322A

[D-Trp34]-Neuropeptide Y TFA	Neuropeptide Y Receptor	Neurological Disease
[D-Trp34]-Neuropeptide Y TFA is a potent and selective neuropeptide Y (NPY) Y₅ receptor agonist. [D-Trp34]-Neuropeptide Y TFA is a significantly less potent agonist at the NPY Y₁, Y₂, Y₄, and y₆ receptors. [D-Trp34]-Neuropeptide Y TFA markedly increases food intake in rats ^[2].

HY-P2426

(D-Trp12,Tyr34)-pTH (7-34) amide (bovine)	Thyroid Hormone Receptor	Metabolic Disease
(D-Trp12,Tyr34)-pTH (7-34) amide (bovine) is a potent and competitive antagonist of parathyroid hormone (PTH), with a K_i of 69 nM in bovine renal cortical membrane. (D-Trp12,Tyr34)-pTH (7-34) amide (bovine) can be used for growth and development regulation ^[2].

HY-P2357

MI-1544	GnRH Receptor	Metabolic Disease
MI-1544 is a powerful GnRH antagonist. MI-1544 induces inhibitory effects on the pituitary LH release and on gonads. MI-1544 can be used for the research of antifertility effect .

HY-P1460

His-[D-2-ME-Trp]-Ala	GHR	Others
His-[D-2-ME-Trp]-Ala is a fragment of the growth hormone hexarelin.

HY-P3901

[Leu8,D-Trp22,Tyr25] Somatostatin-28	Somatostatin Receptor	Neurological Disease
[Leu8,D-Trp22,Tyr25] Somatostatin-28 is the analog of Somatostatin-28. Somatostatin-28 is a intestinal peptide containing somatostatin in its C-terminal portion ^[2].

HY-P3903

[D-Trp8,Tyr11] Somatostatin	Somatostatin Receptor	Endocrinology
[D-Trp8,Tyr11] Somatostatin is an analogue of somatostatin. Somatostatin is a hormone that regulates a variety of bodily functions. DTrp8 residue can increase stability .

HY-P3902

[D-Trp8] Somatostatin-14	Somatostatin Receptor	Neurological Disease
[D-Trp8] Somatostatin-14, a tetradecapeptide, is an analog of Somatostatin more potent than the native Somatostatin .

HY-106103A

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes ^[2] .

HY-P4992

Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11)	Somatostatin Receptor	Cancer
Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a somatostatin agonist that can be used in cancer research .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes ^[2] .

HY-P4442

(Des-Gly10,D-His2,D-Trp6,Pro-NHEt9)-LHRH	GnRH Receptor	Others
(Des-Gly10,D-His2,D-Trp6,Pro-NHEt9)-LHRH is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P4534

(D-His2,D-Trp6)-LHRH (D-His2)-Triptorelin	GnRH Receptor	Others
(D-His2,D-Trp6)-LHRH ((D-His2)-Triptorelin) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P1139

Cortistatin-8 PCFWKTCK	GHSR	Metabolic Disease
Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .

HY-P4201

JKC 301	Vasopressin Receptor	Cardiovascular Disease
JKC 301 is a selective Endothelin A receptor antagonist. JKC 301 attenuates the pressor effects of nicotine in rats. JKC 301 can be used to study cardiovascular disease caused by smoking ^[2].

HY-P10571

GPS1573	Melanocortin Receptor	Endocrinology
GPS1573 is a noncompetitive antagonist of melanocortin type 2 receptor (MC2R) that dose-dependently antagonizes ACTH-stimulated *MC2R* activity (IC₅₀=66 nM). GPS1573 can be used in the study of Cushing's disease due to its highly selective antagonism of *MC2R* .

HY-106244A

DOTATATE acetate 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) ^[2] . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1277

GR 94800	Neurokinin Receptor	Neurological Disease
GR 94800 is a potent and selective *NK₂* receptor peptide antagonist, with pK_B values of 9.6, 6.4 and 6.0 for NK₂, NK₁ and NK₃ receptors, respectively ^[2].

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P1277A

GR 94800 TFA	Neurokinin Receptor	Neurological Disease
GR 94800 TFA is a potent and selective *NK₂* receptor peptide antagonist, with pK_B values of 9.6, 6.4 and 6.0 for NK₂, NK₁ and NK₃ receptors, respectively ^[2].

HY-120301

L-366682	Oxytocin Receptor	Endocrinology
L-366682, a cyclic hexapeptide, possesses antagonism of oxytocin .

HY-P2052

AWL 60	Opioid Receptor Neurokinin Receptor	Others
AWL 60 is a compound with SP antagonist and weak opioid agonist properties, which can antagonize SP-agonists in vitro and attenuate the decrease in blood pressure caused by SP-agonists in vivo.

HY-P10714

Ub4ix	Proteasome Apoptosis Deubiquitinase	Cancer
Ub4ix is a DUB/26S proteasome inhibitor. Ub4ix can protect K48-linked Ub chains from being chopped up by deubiquitinating enzymes (DUBs) and prevent the proteasomal degradation of Ub-tagged proteins. Ub4ix can reduce the viability of Hela cells and induce apoptosis, with an IC₅₀ value of 1.6 μM ^[2].

HY-P3854

GR 83074	Neurokinin Receptor	Neurological Disease
GR 83074 is a potent and selective *NK-2* (Neurokinin Receptor) antagonist with a pK_B of 8.23. GR 83074 is inactive as an NK-3 antagonist and exhibits a 340-fold NK-2/NK-1 selectivity .

HY-106244

DOTATATE 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) ^[2] . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10239A

Tyr3-Octreotate acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity ^[2].

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity ^[2].

HY-P3853

GR 87389	Neurokinin Receptor	Neurological Disease
GR 87389 is a potent NK2 receptor antagonist. GR 87389 antagonized GA 64349-induced smooth muscle strips contractions in a competitive manner in the human detrusor, prostate and prostatic urethra ^[2].

HY-P10920

DOTAMTATE	Drug Derivative	Cancer
DOTAMTATE is a somatostatin analogue. DOTAMTATE marked ²¹²Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .

HY-108055

Urantide	Urotensin Receptor Others	Cardiovascular Disease
Urantide is a selective and competitive urotensin-II (UT) receptor antagonist peptide (pKB=8.3) that blocks human urotensin-II (hU-II)-induced contractions in rat thoracic aorta ex vivo. Urantide can be used to study the (patho)physiological role of hU-II in the mammalian cardiovascular system .

HY-P1959

Lanreotide BIM 23014	Somatostatin Receptor	Endocrinology Cancer
Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome ^[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks